Sweden: Karo Pharma sells hospital supply business

Christoffer Lorenzen, chief executive officer, Karo Pharma

Stockholm-based Karo Pharma has divested Swereco, its hospital supply business unit, to private investment company J2L Holding for SKr150m (US$17.4m). Swereco provides products for rehabilitation, intensive care, diabetes treatment and surgery under the Swereco brand and several in-licensed brands directly to hospitals and regions, is outside of our core business. Handelsbanken Capital Markets ran the…

You must be a HMI Subscriber to view this content.

Subscribe Now »